SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
Find the Keys to Fruitful Venture The board: Conveying Results on Time - 2California warns of death cap mushrooms outbreak resulting in 3 deaths
- 3Drones haven't won the fight in Ukraine. That matters as the West learns new ways of war.
- 4The most effective method to Pick the Right Material Organization: Your Definitive Aide
- 5Greece eyes migrant repatriation centres outside the EU
- The 10 Most Significant Virtual Entertainment Missions
- Australia to offer businesses $693 million in cheap loans to ease fuel cost pressure
- Europe must reinvent warfare for ‘era of shocks,’ NATO’s Vandier says
- What to know about the hepatitis B shot — and why Trump officials are targeting it
- A rare whale is having an encouraging season for births. Scientists warn it might still go extinct
- Pick Your Favored kind of salad
- The Best 20 Tunes that Characterized an Age
- 'Here we go again': Businesses grapple with fuel costs
- As Western heat wave ends, scientists try to make sense of its length and intensity
